05 Aug 2019 – Destiny Pharma welcomes the US government’s healthcare reform for novel antibacterial drug payments

Destiny Pharma welcomes the US government’s healthcare reform for novel antibacterial drug payments which include an alternative pathway for New Technology Add-On Payments (NTAPs) which increases the value of these payments to 75% for Qualified Infectious Disease Products (QIDPs).  This, combined with the UK government 2019 initiative, represents tangible progress to incentivise and reward the developers of novel anti-infectives such as Destiny Pharma.

https://lnkd.in/dYud9ub